As of 2024-12-12, the Relative Valuation of 4D Molecular Therapeutics Inc (FDMT) is (126.59) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.90 USD, the upside of 4D Molecular Therapeutics Inc based on Relative Valuation is -1934.6%.
The range of the Relative Valuation is (129.06) - (143.37) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 28.1x - 44.9x | 34.7x |
| Forward P/E multiples | 19.8x - 31.3x | 20.5x |
| Fair Price | (129.06) - (143.37) | (126.59) |
| Upside | -1970.5% - -2177.9% | -1934.6% |
| Date | P/E |
| 2024-12-11 | -1.50 |
| 2024-12-10 | -1.58 |
| 2024-12-09 | -1.57 |
| 2024-12-06 | -1.60 |
| 2024-12-05 | -1.49 |
| 2024-12-04 | -1.56 |
| 2024-12-03 | -1.54 |
| 2024-12-02 | -1.65 |
| 2024-11-29 | -1.71 |
| 2024-11-27 | -1.72 |
| 2024-11-26 | -1.64 |
| 2024-11-25 | -1.66 |
| 2024-11-22 | -1.70 |
| 2024-11-21 | -1.74 |
| 2024-11-20 | -1.83 |
| 2024-11-19 | -1.89 |
| 2024-11-18 | -1.81 |
| 2024-11-15 | -1.93 |
| 2024-11-14 | -1.75 |
| 2024-11-13 | -1.68 |
| 2024-11-12 | -1.72 |
| 2024-11-11 | -1.76 |
| 2024-11-08 | -1.77 |
| 2024-11-07 | -1.81 |
| 2024-11-06 | -1.82 |
| 2024-11-05 | -1.83 |
| 2024-11-04 | -1.78 |
| 2024-11-01 | -1.76 |
| 2024-10-31 | -1.75 |
| 2024-10-30 | -1.80 |
| 2024-10-29 | -1.79 |
| 2024-10-28 | -1.87 |
| 2024-10-25 | -1.78 |
| 2024-10-24 | -1.79 |
| 2024-10-23 | -1.86 |
| 2024-10-22 | -1.80 |
| 2024-10-21 | -1.87 |
| 2024-10-18 | -1.86 |
| 2024-10-17 | -1.84 |
| 2024-10-16 | -1.89 |
| 2024-10-15 | -1.94 |
| 2024-10-14 | -1.97 |
| 2024-10-11 | -2.00 |
| 2024-10-10 | -1.90 |
| 2024-10-09 | -1.96 |
| 2024-10-08 | -2.05 |
| 2024-10-07 | -2.02 |
| 2024-10-04 | -2.17 |
| 2024-10-03 | -2.25 |
| 2024-10-02 | -2.24 |